Trial Profile
Decay Kinetics of HIV With the Integrase Inhibitor Raltegravir
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Efavirenz; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV infections
- Focus Therapeutic Use
- 25 Oct 2011 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 05 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 24 Mar 2009 New trial record